Carfilsomib (Carfilzomibum)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Other antineoplastic agents

Included in the formulation
  • Kiprolis
    lyophilizate in / in 
    Amgen Europe BV     Netherlands
    • АТХ:

    L.01.X.X.45   Carfilsomib

    Pharmacodynamics:

    Selectively and irreversibly connects N-terminal threonine of the active sites of the main proteolytic subunit 20S, which is part of the proteasome 26S. This slows down the growth of malignant myeloma cells, solid tumors and hemoblastoses.

    Not active against non-proteasomal proteases.

    Pharmacokinetics:

    After intravenous administration, the maximum concentration in the blood plasma is reached after 5-10 minutes. The connection with plasma proteins is 97%.

    Metabolism in the liver to inactive metabolites.

    The elimination half-life is 1 hour. Elimination by the kidneys.

    Indications:

    It is used to treat multiple myeloma.

    ICD-10

    II.C81-C96.C90.0   Multiple myeloma

    Contraindications:

    Age under 18 years, pregnancy and lactation, individual intolerance.

    Carefully:

    Dysfunction of the liver, hypersensitivity.

    Pregnancy and lactation:

    Recommendations for FDA - Category C. Contraindicated in pregnancy and lactation.

    Dosing and Administration:

    Intravenously, 20 mg / m2 duration of 10 minutes for 2 days, then once a week for 3 weeks, after which a break for 12 days is done.

    The highest daily dose: 20 mg / m2.

    The highest single dose: 20 mg / m2.

    Side effects:

    Central and peripheral nervous system: dizziness, insomnia, anxiety, peripheral neuropathy, acute violation of cerebral circulation.

    Respiratory system: cough, shortness of breath, interstitial pneumonitis.

    Hemopoietic system: thrombocytopenia, anemia, lymphopenia, neutropenia, thrombocytopenic purpura.

    The cardiovascular system: arterial hypertension, hypertensive crisis, tachycardia, atrial fibrillation, myocardial infarction, pericarditis.

    Digestive system: dyspepsia, toothache, diarrhea, constipation, rarely - perforation of the gastrointestinal tract.

    Musculoskeletal system: arthralgia, myalgia, ossalgia, muscle spasms.

    Dermatological reactions: hyperhidrosis, itching, rash.

    Sense organs: cataract, visual impairment.

    urinary system: renal failure.

    Allergic reactions.

    Overdose:

    Chills, kidney failure, cardiac arrest.

    Treatment is symptomatic.

    Interaction:

    Clinically significant interactions are not described.

    Special instructions:

    When taking the drug is not recommended driving and working with moving machinery.

    Instructions
    Up